Amundi Buys 16,599 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Amundi raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 30.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,266 shares of the medical research company’s stock after buying an additional 16,599 shares during the quarter. Amundi owned about 0.14% of Charles River Laboratories International worth $13,204,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. raised its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $59,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CRL. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group lowered their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Price Performance

Shares of CRL opened at $171.27 on Friday. The firm has a market capitalization of $8.76 billion, a PE ratio of 1,141.78, a PEG ratio of 4.54 and a beta of 1.45. The company’s 50-day moving average is $167.74 and its 200-day moving average is $184.72. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the company posted $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).